Lundbeck's Carnexiv injection -- an orally administered replacement therapy for short-term use to treat adults with specific types of seizures -- has been approved by the U.S. Food and Drug Administration. Read More »
Corvus Pharmaceuticals has released its biomarker findings in its ongoing Phase 1/1b clinical trial involving CPI-444, as both a single agent and as a combination with TECENTRIQ, a Genentech product that is a fully humanized monoclonal antibody developed to target cell death ligand 1 protein. Read More »
UnitedHealth Group this week released its third quarter results, reporting that the company has experienced growth at a well-balanced level and steady execution in all areas of its various businesses. Read More »
Medicaid could see $51.1 billion over the next decade if a “full range of pharmacy benefit management tools” is employed, according to a new report completed by The Menges Group and released by the Pharmaceutical Care Management Association (PCMA). Read More »
Pharmacy benefit managers (PBMs) are proven in helping the control rising prescription drug prices and should be part of the solutions adopted by policymakers, writes Pharmaceutical Care Management Association (PCMA) President Mark Merritt in an op-ed published yesterday in The Hill. Read More »
Hepatitis C medication costs in 2015 proved lower for the U.S. than Europe and Japan, particularly prices negotiated by pharmacy benefit managers in Medicare Part D, the Pharmaceutical Care Management Association recently reported. Read More »
The U.S. Food and Drug Administration has sent Nicox S.A. a Complete Response Letter in regard to its AC-170 New Drug Application. Read More »
Pfizer has released data from its Phase 1b INLYTA clinical trial in which the drug is combined with pembrolizumab, a PD-1 inhibitor called KEYTRUDA, and marketed by Merck. Read More »
The Medicines Co. recently released update information regarding its ORION-1 clinical trial, which revolves around PCSK9si, the company’s investigational PCSK9 synthesis inhibitor. Read More »
WomenHeart: The National Coalition for Women with Heart Disease has received a community grant from CVS Health to help build healthier communities and support nonprofit organizations assisting underserved populations receive health care. Read More »
Coherus BioSciences has filed of its 351(k) Biologics License Application for its pegfilgrastim biosimilar candidate CHS-1701 has been accepted by the U.S. Food and Drug Administration. Read More »
Allergan will continue its collaborative efforts with Dystonia Medical Research Foundation to support patients with dystonia by conducting a survey that will assess cervical dystonia awareness, its symptoms and options for treatment that will inspire education and the correct diagnosis of the condition, which can often be disabling. Read More »
.jpg)
The buprenorphine/naloxone CIII sublingual tablet ZUBSOLV from Orexo US has been approved by the U.S. Food and Drug Administration. Read More »
Kite Pharma has enrolled its first patient into the Phase 1b/2 ZUMA-6 clinical trial involving KTE-C19. Read More »
In the wake of Hurricane Matthew, CVS Health reminds its customers to properly prepare their prescriptions and take care of their needs when storms are approaching their areas. Read More »
In the wake of Hurricane Matthew bearing down on the East Coast, Walgreens is reminding its pharmacy patients about how important prescription preparedness is in times like these. Read More »
Catabasis Pharmaceuticals' Andrew Nichols has been named the company’s new chief scientific officer and Angelika Fretzen has been named senior vice president of product development. Read More »
Recent data from the Baltimore, Maryland-based Centers for Medicare & Medicaid Services (CMS) suggests that over eight out of ten Medicare Part D regional prescription drug plans (PDP) will utilize preferred network plans in 2017. Read More »
Eli Lilly and Co. will present data at the European Society of Medical Oncology’s 2016 Congress in Copenhagen from a number of clinical studies that will serve to further strengthen the development of its diverse clinical cancer portfolio. Read More »
CymaBay Therapeutics has determined the next course for the development of MBX-8025 in patients with primary biliary cholangitis after the U.S. Food and Drug Administration gave the company input on the process. Read More »
Alerts Sign-up
